Chocolate and Prevention of Cardiovascular Disease: A Systematic Review by Ding, Eric L et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
Nutrition & Metabolism
Open Access Review
Chocolate and Prevention of Cardiovascular Disease: A Systematic 
Review
Eric L Ding*1,2, Susan M Hutfless1, Xin Ding1 and Saket Girotra3
Address: 1Department of Epidemiology, Harvard University, School of Public Health, Boston, MA, USA, 2Department of Nutrition, Harvard 
University, School of Public Health, Boston, MA, USA and 3Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
Email: Eric L Ding* - eding@jhu.edu; Susan M Hutfless - shutfles@hsph.harvard.edu; Xin Ding - xinding@hsph.harvard.edu; 
Saket Girotra - sgirotra@post.harvard.edu
* Corresponding author    
Abstract
Background: Consumption of chocolate has been often hypothesized to reduce the risk of
cardiovascular disease (CVD) due to chocolate's high levels of stearic acid and antioxidant
flavonoids. However, debate still lingers regarding the true long term beneficial cardiovascular
effects of chocolate overall.
Methods: We reviewed English-language MEDLINE publications from 1966 through January 2005
for experimental, observational, and clinical studies of relations between cocoa, cacao, chocolate,
stearic acid, flavonoids (including flavonols, flavanols, catechins, epicatechins, and procynadins) and
the risk of cardiovascular disease (coronary heart disease (CHD), stroke). A total of 136
publications were selected based on relevance, and quality of design and methods. An updated
meta-analysis of flavonoid intake and CHD mortality was also conducted.
Results: The body of short-term randomized feeding trials suggests cocoa and chocolate may
exert beneficial effects on cardiovascular risk via effects on lowering blood pressure, anti-
inflammation, anti-platelet function, higher HDL, decreased LDL oxidation. Additionally, a large
body of trials of stearic acid suggests it is indeed cholesterol-neutral. However, epidemiologic
studies of serum and dietary stearic acid are inconclusive due to many methodologic limitations.
Meanwhile, the large body of prospective studies of flavonoids suggests the flavonoid content of
chocolate may reduce risk of cardiovascular mortality. Our updated meta-analysis indicates that
intake of flavonoids may lower risk of CHD mortality, RR = 0.81 (95% CI: 0.71–0.92) comparing
highest and lowest tertiles.
Conclusion: Multiple lines of evidence from laboratory experiments and randomized trials suggest
stearic acid may be neutral, while flavonoids are likely protective against CHD mortality. The
highest priority now is to conduct larger randomized trials to definitively investigate the impact of
chocolate consumption on long-term cardiovascular outcomes.
Introduction
Cardiovascular disease (CVD), as a group, is a leading
cause of the death in the United States [1], and worldwide,
causing over 16.7 million deaths globally in 2002 [2]. In
1990, greater than 85,000,000 disability-adjusted life-
years were lost worldwide due to coronary heart disease
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(CHD) and stroke; this CVD disease burden is projected
to rise to 143,000,000 disability-adjusted life-years by
2020 [2]. Studies suggest cardiovascular diseases may be
preventable by lifestyle modifications, such as exercise
and nutrition [3-7]. Additionally, the American Heart
Association, American Diabetes Association, and the U.S.
Preventive Services Task Force have each indicated the
likely importance of diet for the prevention of CVD [8-
10].
In the American diet, fruits, vegetables, tea, wine and
chocolate are major sources of antioxidants, which have
been shown to have protective effects against CVD
[11,12]. One class of antioxidants, flavonoids, commonly
found in such foods, have attracted great interest in poten-
tially lowering risk of CVD. Since cocoa products contain
greater antioxidant capacity and greater amounts of flavo-
noids per serving than all teas and red wines [12,13], it is
important to explore chocolate's potential effects on CVD.
Since ancient times, chocolate has long been used as a
medicinal remedy [14] and been proposed in medicine
today for preventing various chronic diseases [15,16].
While chocolate has also sometimes been criticized for its
saturated fat content, mostly in the form of long-chain
stearic acid, chocolate has also been lauded for its antioxi-
dant potential. However, to this date there are no long-
term randomized feeding trials of chocolate to assess
effects on actual cardiovascular events. Nevertheless, there
have been many short-term trials of cocoa and chocolate
examining effects on cardiovascular intermediates, and
numerous epidemiology studies of stearic acid and flavo-
noids exploring associations with cardiovascular out-
comes.
This systematic review serves to comprehensively evaluate
the experimental and epidemiologic evidence of cocoa
and chocolate products. Particularly, we focus on the con-
troversial potential benefits of the chocolate components
stearic acid and flavonoids; review their overall effects on
CVD risk factor intermediates and CVD endpoints; and
conduct a meta-analysis of total flavonoid intake and risk
of CHD mortality.
Methods
We reviewed English-language MEDLINE publications
from January 1965 through June 2005 for experimental,
observational, and clinical studies of relations between
the exposure search terms of chocolate, stearic acid, flavo-
noids (including flavonols, flavanols, catechins, epicate-
chins, and procynadins) and the outcome search terms of
cardiovascular disease (coronary heart disease, ischemic
heart disease, stroke), cholesterol, blood pressure, plate-
let, oxidation, and thrombosis. Approximately 400 papers
were reviewed. Based on the relevance, strength, and qual-
ity of the design and methods, 136 publications were
selected for inclusion.
We mainly focused on studies in humans, particularly
randomized trials of either parallel or cross-over design,
and prospective observational studies. Since no rand-
omized trials have yet assessed chocolate in relation to
definitive CVD outcomes, prospective observational stud-
ies evaluating chocolate sub-components and the risk of
CVD outcomes were weighted equally in the overall eval-
uation. For overall objective evaluation, the strength of
the evidence was evaluated by the design and quality of
individual studies, the consistency of findings across stud-
ies, and the biologic plausibility of possible mechanisms.
Finally, consistent with methods of the outdated prior
analysis [17], an updated meta-analysis was conducted
and relative risks estimates pooled using a random-effects
model [18].
Review
Stearic acid in chocolate
Saturated fat has long been thought to contribute to
atherosclerosis, and thus, adverse for CVD risk. However,
stearic acid has been suggested to be a non-atherogenic
type of dietary saturated fat. Stearic acid is a long-chain
18:0 saturated fatty acid found commonly in meats and
dairy products. Cocoa butter, a fat derived from cocoa
plants and predominantly found in dark chocolate [19],
contains an average of 33% oleic acid (cis-18:1 monoun-
saturated), 25% palmitic acid (16:0 saturated), and 33%
of stearic acid [20]. Thought it is generally considered that
saturated fats overall adversely increase the total choles-
terol and LDL levels [21-23], early studies have also sug-
gested stearic acid may be non-cholesterolemic [21,22].
This has been confirmed in a series of studies and a meta-
analysis of 60 controlled feeding trials which concludes
stearic acid neither lowers HDL, nor increases LDL or total
cholesterol [24-28]. The meta-analysis also estimates, that
per 1% energy isocaloric replacement of stearic acid for
carbohydrates, stearic acid intake is predicted to benefi-
cially lower serum triglycerides by -17.0 nmol/L (p <
0.001) [26]. The most recent trial also shows the effects of
stearic acid on lipids is even similar to oleic and linoleic
acids [29].
Emerging studies have begun to explain how stearic acid
in chocolate may be cholesterol-neutral. One suggested
mechanism is stearic acid's lower absorption, which has
been found in several animal and human studies [30-33],
though only minimally in others [34,35]. These discrep-
ancies may be attributed to the relative position of stearate
on the triglyceride molecule which may affect its relative
absorption rate [36,37]. This might also explain the sug-
gestion that stearic acid from plants sources, such as
cocoa, may be different from animal derived sources ofNutrition & Metabolism 2006, 3:2 http://www.nutritionandmetabolism.com/content/3/1/2
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Table 1: Summary of Chocolate and Cocoa Feeding Trials
Author Year No. 
Participants
Trial 
Design
Duration Intervention Outcome(s)
Kondo [83] 1996 12 Crossover 1 meal, pre/post-
meal measurement
Cocoa (35 g delipidated), vs. 
none
Decreased LDL oxidation
Rein [138] 2000 30 Parallel 1 meal, 2 & 6 hrs Cocoa beverage (300 ml, 19 g 
procyanidin), caffeinated 
beverage (17 mg caffeine), or 
water
Decreased platelet activation, 
decreased platelet function
Wang [79] 2000 20 Crossover 1 meal, 1 week/
phase
Procyanidin-rich chocolate (27, 
53, 80 g), vs. none
Increased antioxidant capacity, 
decreased oxidative stress
Osakabe [88] 2001 15 Parallel daily, 2 weeks Cocoa powder (36 g/day), vs. 
sugar
Decreased LDL oxidation 
(increased lag time)
Wan [85] 2001 23 Crossover daily, 4 weeks/
phase
Cocoa powder (22 g/day) + dark 
chocolate (12 g/day), vs. average 
American diet
Decreased LDL oxidation 
(increased lag time), Increased 
HDL concentration
Schramm [101] 2001 10 Crossover 1 meal, 2 & 6 hrs, 
1 week/phase
Chocolate (35 g, high 4 mg/g vs. 
low 0.09 mg/g procyanidin)
Increased prostacyclin, 
decreased leukotriene (likely 
decreased platelet activation, 
anti-inflammatory)
Holt [95] 2002 18 Crossover 1 meal, 2 hrs Chocolate chips (25 g semi-
sweet), vs. none
Decrease platelet function
Mathur [86] 2002 25 Crossover daily, 6 weeks/
phase
Dark chocolate (37 g/day), cocoa 
powder (31 g/day), vs. none
Decreased LDL oxidizability, 
marginal HDL increase
Pearson [92] 2002 16 Crossover 1 meal, 1 day/
phase
Cocoa beverage (300 ml, 19 g 
flavanol cocoa powder), cocoa 
beverage + aspirin, or aspirin
Decreased platelet activation, 
decreased platelet function, all 
additive of aspirin effects.
Heiss [99] 2003 20 Crossover 1 meal, 1 day/
phase
Cocoa beverages (100 ml, high 
or low flavan-3-ol)
Increased NO bioactivity, 
improved endothelial function
Innes [97] 2003 30 Parallel 1 meal, 4 hrs Dark (75% cocoa, highest 
flavonoid content), milk (20% 
cocoa), or white chocolate (no 
flavonoids)
Dark chocolate inhibited 
collagen-induced platelet 
aggregation
Murphy [94] 2003 32 Parallel daily, 28 days Cocoa flavonoid tablets (234 
mg), vs. placebo
Decreased platelet function, no 
difference oxidation status
Serrafini [76] 2003 12 Crossover 1 meal, 1 day/
phase
Dark chocolate (100 g), dark 
chocolate (100 g) + milk (200 
ml), or 200 g milk chocolate
Increase antioxidant capacity, in 
absence of milk
Taubert [118] 2003 13 Crossover daily, 14 days/
phase
Dark chocolate (100 g, 500 mg 
polyphenols), vs. white chocolate 
(90 g, 0 mg polyphenols)
Lower systolic and diastolic 
blood pressure with dark 
chocolate
Wiswedel [90] 2004 20 Crossover 1 meal, 1 week 
washout
High flavanol (1.87 mg/ml) vs. 
low flavanol (0.14 mg/ml) cocoa 
beverage
Lower levels of lipid 
peroxidation indicators with high 
flavanol cocoa beverage
Engler [98] 2004 21 Parallel daily, 2 weeks Chocolate (high vs. low 
flavonoid)
Improved endothelial function, 
no difference oxidative stress, 
lipids with high flavonoid choc.
Mursu [115] 2004 45 Parallel daily, 3 weeks Dark chocolate, dark chocolate 
enriched with cocoa 
polyphenols, or white chocolate
Increased HDL concentration, 
no change LDL oxidizability
Grassi [116] 2005 15 Crossover daily, 15 days/
phase
Dark chocolate (100 g, 500 mg 
polyphenols), vs. white chocolate 
(90 g, 0 mg polyphenols)
Lower systolic blood pressure, 
improved insulin sensitivity, 
lower insulin resistance
Zhu [139] 2005 8 Parallel 1 meal, 1–2–4–8 
hrs
Cocoa beverage (high flavonoid); 
0.25, 0.38, 0.50 g/kg body weight 
dose
Reduced susceptibility to free-
radical induced hemolysis
Vlachopoulos 
[140]
2005 17 Crossover 1 meal, 1 day/
phase
Dark chocolate (100 g, 2.62 g 
procyanidin), vs. none
Improved endothelial function, 
vasodilation of brachial artery, 
no change in blood pressure
Fraga [119] 2005 28 Parallel daily, 14 days High flavanol milk chocolate (105 
g, 168 mg flavanols) vs. low 
flavonoid chocolate (<5 mg 
flavanols)
Lower mean blood pressure, 
lower LDL cholesterol, lower 
oxidative stress markers in high 
flavanol chocolate groupNutrition & Metabolism 2006, 3:2 http://www.nutritionandmetabolism.com/content/3/1/2
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stearic acid [38]. Furthermore, some feeding trials found
lower absorption of cocoa buttered compared to corn oil
[39], though not in others [40]. However, heterogeneity
may be due to the dual-presence of calcium in chocolate,
in which other trials found cocoa butter absorption fur-
ther decreased 13% when supplemented with calcium
(1% by weight) [41], as is done in chocolate manufactur-
ing. Finally, another strongly supported protective mech-
anism relate to the relatively high percent desaturation of
stearic acid to monosaturated oleic acid [35,42-45], a fat
considered hypocholesterolemic [27,46-48] and protec-
tive against coronary heart disease [3,49].
Two other pathways suggested for potential benefit are
stearic acid's potential anti-platelet and blood pressure
reductions actions. Feeding trials have shown that stearic
acid reduces mean platelet volume [50,51], an index of
platelet activation. However, mixed findings have been
observed regarding the relationship between stearic acids
and factor VIIc coagulation factor, a predictor of fatal
CHD [52-54]. Though an early study suggested that stearic
acid may increase factor VIIc [55], no effect on levels of
factor VIIc by stearic acid was observed in two other trials
[56,57]. Moreover, additional trials have refuted the ear-
lier small study and, in fact, shown that stearic acid low-
ered the levels of factor VIIc coagulation factor compared
to palmitic [50,58] and other saturated fatty acids [58]. As
for the relationship between stearic acid and blood pres-
sure, two feeding trials found stearic acid did not
adversely affect systolic blood pressure [28,59]. Further-
more, cross-sectional analysis within the Multiple Risk
Factor Intervention Trial even found stearic acid levels
may be inversely associated with diastolic blood pressure
[60].
In summary, given the vast majority of studies showing
stearic acid has beneficial or neutral effects on blood pres-
sures and clotting parameters, it appears unlikely stearic
acid intake would adversely affect CVD risk through these
risk factors. Data indicates stearic acid does not adversely
affect established traditional lipid risk factors, with even
favorable lowering of serum triglycerides if isocalorically
replaced for carbohydrates.
Stearic Acid Observational Studies
However, the observational studies of stearic acid's associ-
ation with CVD are inconclusive. (Table 2) Among retro-
spective studies, a Japanese case-control study of serum
levels reported no association for stenosis [61], a Norwe-
gian study found lower odds of MI [62], while a Costa
Rican study of dietary intake found higher risk of MI [63]
with higher intake of stearic acid. However, the results
from the Costa Rican study should not be given much
weight since retrospective self-report of dietary intakes are
notoriously inaccurate and susceptible to reporting bias
[64]. Nevertheless, higher rates of CHD and CAD progres-
sion was found in several prospective studies [65-68],
while stroke was not increased in another study [69].
On the other hand, several limitations exist for observa-
tional studies of stearic acid. First, researchers have cau-
tioned that analyses of dietary stearic acid are very difficult
due to high correlations of stearic acid intake with other
fatty acids (often r = 0.7 to 0.9), thus impeding optimal
study of associations [65]. Additionally, the larger pro-
spective study that found higher risk of CHD also noted
chocolate was a very small contributor (5%) of total
stearic acid intake, with red meats as primary sources of
stearic acid. Finally, since there exists high interconversion
of stearic acid to unsaturated fatty acids [35,42-45], stud-
ies involving serum levels of stearic acid do not answer the
relevant causal question of dietary intake of stearic acid
and risk of disease. The associations of long-term serum
stearic acid levels represent the effects of post-conversion
stearic acid levels after a large proportion of the original
dietary stearic acid has already been converted away to
monounsaturated fat, which is well-established to exert
protective effects against CVD [3,27,46-49].
Table 2: Observational Studies of Stearic Acid and Cardiovascular Outcomes
Author Year Study 
design
N, Population Stearic acid 
assessment 
method
CHD/MI 
Outcomes
Other
Kromhout [141] 1995 Ecologic 12,763 men, 16 cohorts of 7CS Dietary intake ↑ CHD mortality
Simon [68, 69] 1995 Prospective 96 cases, 96 controls, USA-MRFIT Serum levels ↑ CHD incidence Null-stroke incidence
Watts [67] 1996 Prospective 50 men, Australia Dietary intake ↑ CAD progression
Hojo [61] 1998 Case-control 71 cases, 60 controls, Japan Serum levels Null-stenosis
Hu [65] 1999 Prospective 80,082 women, USA-nurses Dietary intake ↑ CHD incidence
Yli-Jama [62] 2002 Case-control 103 cases, 104 controls, Norway Serum levels ↓ MI incidence
Kabagambe [63] 2003 Case-control 485 cases, 508 controls, Costa Rica Dietary intake ↑ MI incidence
Wang [66] 2003 Prospective 3591 whites, USA Serum levels ↑ CHD mortality
Abbreviations: 7CS, 7 Countries Study; MRFIT, Multiple Risk Factor Intervention Trial;
* High stearic acid level among men from geographic areas of high IHD mortalityNutrition & Metabolism 2006, 3:2 http://www.nutritionandmetabolism.com/content/3/1/2
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Thus, relatively little information can be inferred from
observational studies of the association of stearic acid and
CHD, and no epidemiologic study has, thus far, appropri-
ately and optimally answered the causal question of the
association of dietary stearic acid intake and risk of CVD.
However, a sufficient body of strong evidence from short
term randomized trials suggests stearic acid components
in chocolate may be beneficial for cardiovascular health.
However, further research in this area is warranted.
Flavonoids in chocolate
A 100 g bar of milk chocolate contains 170 mg of flavo-
noid antioxidants, procyanidins and flavanols [12]. It is
estimated that chocolate is a leading source of procyani-
din intake in Western nations (18–20%) [70,71]. Flavo-
noids belong to a class of antioxidants called polyphenols
from plants [72]. The basic structure of flavonoids is a C6-
C3-C6 backbone with two armomatic rings and varying
degrees of hydroxylation differentiating one flavonoid
type from another [73]. Flavonoids can be divided into
various subclasses, important of which are flavones, fla-
vonols, flavanones, catechins, anthocyanidins and isofla-
vones. Cocoa, is particularly rich in the flavonoids,
epicatechin, catechin, and procyanidins (polymers of cat-
echins and epicatechins) [74]. (Figure 1)
Various studies have compared the content of the fla-
vanoids in cocoa with other food stuffs quantitatively. Fig-
ure 2 shows the comparative content of flavonoids in milk
chocolate and dark chocolate versus other high-flavonoid
foods. Cocoa has been shown to have the highest content
of polyphenols (611 mg/serving) and flavanoids (564
mg/serving of epicatechin), greater than even tea and wine
[13]. Per serving, dark chocolate contains substantially
higher amounts of flavonoids than milk chocolate (951
mg of catechins per 40 g serving compared to 394 mg in
white chocolate) [75], and levels of epicatechin in dark
chocolate is comparable to red wine and tea [75]. Also of
note, dark chocolate contains significantly greater
amounts of total phenols as well as catechins than milk
chocolate per serving (126+-7.4 µmol/g vs. 52.2+-20.2
µmol/g) [75]. In addition to dark chocolate having higher
flavonoid content, the biologic effects of flavonoids may
also be greater in dark chocolate because milk in milk
chocolate may inhibit the intestinal absorption of fla-
vanoids [76]. Finally, chocolate is also abundant in procy-
anidin flavonoids, comparable with levels in procyanidin-
rich apples [77]. Thus, chocolate is a rich source of flavo-
noids, particularly catechins, epicatechins and procyani-
dins.
Structural skeleton of flavonoids and classification hierarchy of common flavonoids Figure 1
Structural skeleton of flavonoids and classification hierarchy of common flavonoids. *Flavanol is the predominate 
class of flavonoid found in cocoa and chocolate.Nutrition & Metabolism 2006, 3:2 http://www.nutritionandmetabolism.com/content/3/1/2
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Mechanisms
Chocolate flavonoids have shown good dose-response
bioavailability in humans [11,78,79]. There exists several
mechanisms of how flavonoids may be protective against
CVD; these include: antioxidant, anti-platelet, anti-
inflammatory effects, as well as possibly increasing HDL,
lowering blood pressure, and improving endothelial func-
tion. The body of trials involving chocolate flavonoids is
summarized in Table 1.
Central to the pathogenesis of atherosclerosis is the oxida-
tion of low-density lipoprotein (LDL). The chemical struc-
ture of flavonoids gives the compound free radical
scavenging ability, which means flavonoids may have
antioxidant effects [80]. Various studies have confirmed
the role of flavanoids as antioxidants in biological sys-
tems. Flavanoids in chocolate have been shown to exert
potent antioxidant effects in vitro assays under artificial
oxidative stress [13,81-84] as well increase antioxidant
capacity as part of various chocolate feeding trials [79,85-
89]. Additionally, because lipid soluble flavonoids may
intercalate into the membranes of lipoprotein particles,
studies have shown flavonoids to decrease lipid peroxida-
tion of biological membranes [90]. Furthermore, a rand-
omized trial also demonstrated that flavonoid-rich foods
can protect human lymphocytes from oxidative damage
in vivo [91].
Additionally, aggregation of platelets at the site of plaque
rupture and endothelial dysfunction has been implicated
in the pathogenesis of atherosclerosis. Current research
has shown that a number of components of chocolate,
particularly catechin and epicatechin, have significant
antiplatelet effects, quantitatively similar to that of aspirin
[92]. Randomized trials studying platelet activation mark-
ers, microparticle formation and primary platelet aggrega-
tion as end points have found that daily intake of cocoa
beverages produces a significant reduction in all these
endpoints among healthy volunteers [93-96]. There were
also significant correlations between the reduction in
these end points and the plasma concentrations of cate-
chin and epicatechin [93-96]. Another study found a sig-
nificant reduction in platelet activation in groups
consuming 100 g of dark chocolate when compared to
those consuming similar amounts of white chocolate and
milk chocolate [97]. In addition, randomized trials have
also shown that consumption of high-flavanoid dark
chocolate is associated with a significant improvement of
endothelial function, marked by increase in brachial
artery flow mediated dilation [98-100], likely mediated by
chocolate flavonoids increasing local production of nitric
oxide [99,100].
Chocolate may also influence levels of leukotrienes and
prostacyclins. Leukotrienes are potent vasocontrictors,
proinflammatory agents and stimulate platelet aggrega-
tion, whereas prostacyclin is a vasodilator and inhibits
platelet aggregation. Consumption of chocolate with high
procyanidin content (147 mg) was shown in a feeding
trial to significantly lower the levels of leukotrienes (29%)
and increase the levels of prostacyclin (32%) when com-
pared to a group consuming a low procyanidin (3.3 mg)
chocolate [101]. In vitro studies have indeed demon-
strated chocolate components to inhibit lipoxygenase
pathways, which gives rise to proinflammatory leukot-
rienes [102,103]. Inflammation is now recognized as
another independent mechanism in the pathogenesis of
atherosclerosis, with various inflammatory markers hav-
ing been shown to predict risk of future CVD events [104-
108]. In addition to anti-inflammatory effects on the
lipoxygenase pathway, cocoa polyphenols have also been
shown to decrease inflammation via several mechanisms,
namely: inhibition of mitogen induced activation of T
cells, polyclonal activation of B cells, reduced expression
of interleukin-2 (IL-2) messenger RNA, and reduced secre-
tion of IL-2 by T cells[109] Other have also found choco-
late procyanidins can modulate of a variety of other
Flavonoid content and antioxidant capacity (ORAC) of milk  chocolate and dark chocolate versus other high flavonoid  foods Figure 2
Flavonoid content and antioxidant capacity (ORAC) 
of milk chocolate and dark chocolate versus other 
high flavonoid foods. * Brewed, per 2 g bag/200 ml water. 
Antioxidant activity is reported as oxygen radical absorbance 
capacity (ORAC). Adapted from: Steinberg et al. J Am Diet 
Assoc 103: 215-23.N
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Table 3: Prospective Studies of Flavonoids and Cardiovascular Outcomes
Author Year Study type N, Population Follow-up 
Years
Flavonoid 
Type
CHD/MI 
Incidence
CHD/MI 
Mortality
Stroke 
Mortality
Comments:
Hertog [125, 142]*, Keli 
[127]
1993, 1996 Prospective 552 to 806 Men, Dutch 5, then 10* Total Flavonoids ↓↓↓*Update 1997 analysis finds even 
stronger CHD association [142]
Knekt [131] 1996 Prospective 5133 M+W, Finland 26 Total Flavonoids ↓
Rimm [123] 1996 Prospective 34789 Men, USA 6 Total Flavonoids Null ↓* *marginal significance, if past 
history of CVD
Hertog [133] 1997 Prospective 1900 Men, UK 14 Total Flavonoids Null ↑* *marginal significance, *milk 
consumed w/tea
Yochum [130] 1999 Prospective 34492 PostM women, 
Iowa
10 Total Flavonoids ↓ Null
Hirvonen [126, 129] 2000, 2001 Prospective 23596 Men, Finland 6.1 Total Flavonoids ↓ MI ↓* Null *suggestive, but non-significant
Arts [143] 2001 Prospective 806 men, Dutch 10 Catechins 
(Flavonoid)
↓ Null
Arts [128] 2001 Prospective 34492 PostM women, 
Iowa
13 Catechins 
(Flavonoid)
↓
Geleinjse [122] 2002 Prospective 4807 M+W, Dutch 5.6 Total Tea 
Flavonoids
Null ↓
Knekt [132] 2002 Prospective 10054 M+W Finland 28 Specific 
flavonoids
↓↓also ↓ type 2 diabetes
Sesso [124] 2003 Prospective 38445 women, USA 6.9 Total Flavonoids Null Null Null
META-ANALYSIS (updated)** Total Flavonoids → CHD Mortality RR = 0.81 (95% CI: 0.71–0.92)* (extreme tertiles)
**Updated meta-analysis includes: all studies of "total flavonoids" and CHD mortality; comparison of top vs. bottom tertile.Nutrition & Metabolism 2006, 3:2 http://www.nutritionandmetabolism.com/content/3/1/2
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cytokines (e.g. IL-5, TNF-α, TGF-β), reducing their inflam-
matory effects [110-114].
Furthermore, multiple cocoa feeding trials have also
found chocolate to increase HDL cholesterol [85,86,115],
and decrease blood pressure [116-119]. Finally, there are
also suggestive findings in a few trials that indicate high-
flavonoid chocolate may also lower LDL cholesterol
[119], and improve insulin sensitivity [116].
Thus, the large body of evidence from laboratory findings
and randomized trials suggest that high-flavonoid choco-
late may protect against LDL oxidation, inhibit platelet
aggregation, improve endothelial function, increase HDL,
lower blood pressure, and reduce inflammation – thereby
protective against risk of CVD.
Flavonoid Observational Studies
Mechanistic studies involving stearic acid and flavonoids
have only assessed effects on intermediate cardiovascular
endpoints. However, one cannot always assume effects
from short term trials effects will necessarily translate into
long term effects on CVD outcomes. Therefore, one needs
to examine observational studies followed to CVD events.
While one small study found moderate consumption of
candy and chocolate was associated with lower all-cause
mortality [120], this analysis neither isolates chocolate
nor CVD events. Thus, in absence of specific studies of
chocolate flavonoids and risk of CVD, studies of all flavo-
noids are the best available evidence to infer risk.
The prospective studies of flavonoids and risk of CVD are
summarized in Table 3. The earliest international ecologic
study suggested flavonoid intake may be associated with
lower rates of CHD mortality [121]. While some studies
report flavonoid intake is not associated with CHD inci-
dence [122-124], two other prospective studies suggested
flavonoids may lower risk of MI [125,126]. For stroke, the
evidence is fairly consistent. Other than one small early
study which found a significantly lower risk of stroke with
higher total flavonoid intake [127], most studies indi-
cated no association for risk of stroke [124,128-130].
However, most of these studies had insufficient power to
adequately study stroke, nor enough power to stratify on
various subtypes of stroke with different etiologies.
However, the most extensively consistent finding is the
association between flavonoid intake and CHD mortality.
A total of eight cohort studies found risk of lower CHD
mortality with total or specific flavonoid intake
[71,121,123,125,126,128,130-132], with one study find-
ing marginally protective association among men with
prior CVD conditions [123]. Only one study reported
absolutely no association between flavonoid intake and
CHD mortality [133]. However, as noted by the authors of
one of the studies, a high background consumption of
milk with tea intake may have led to the null finding
[133], since milk intake has been shown to prevent the
intestinal absorption of flavonoids [76].
A meta-analysis of the 7 prospective studies prior to Sep-
tember 2001 found that, overall, flavonoids may be pro-
tective against CHD mortality [17]. However, this meta-
analysis did not include a large subsequent cohort study
of 38,445 women [124], which found a non-significant
inverse association between flavonoid intake and CHD
mortality. However, results from our updated meta-anal-
ysis still indicate a significant protective association exists
between flavonoid intake and risk of CHD mortality, RR
= 0.81 (95% CI: 0.71–0.92), comparing highest vs. lowest
tertiles.
However, a limitation of inference exists in that flavo-
noids consists of a wide variety of polyphenol com-
pounds, the variety of which may differ between studies
due to varying sources of dietary flavonoids. Nonetheless,
dark chocolate does contain substantially more flavanols
than tea, apple, onions, and red wine [12]. Additionally,
chocolate has all the flavonoids of tea [134], has 4 times
the catechins of tea [134], has many flavonoids not found
in tea [135], and substantially contributes to the total fla-
vonoid intake in the diet of many countries [136]. How-
ever, inference from observational studies on the
protective effect of flavonoids in chocolate on CVD risk is
somewhat indirect and may need to be examined by fur-
ther studies.
Overall, these epidemiologic findings, combined with the
large body of evidence from short term randomized choc-
olate feeding trials, suggests flavonoid intake from choco-
late is likely protective against CVD, particularly CHD
mortality. Additionally, given that dark chocolate has sub-
stantially higher levels of flavonoids than milk chocolate,
and that milk may inhibit absorption of flavonoids – it
would be more prudent to consume high flavonoid dark
chocolate rather than milk chocolate.
Conclusion
According to the International Cocoa Organization, pro-
duction has risen from 1.2 million tons per year in 1960
to 3.2 million tons per year in 2004 [137]. Given the rap-
idly increasing world consumption of chocolate and ris-
ing global rates of CVD, it is important to establish
chocolate's association with CVD risk. The projected
increase in global consumption could have profound
effects if chocolate consumption does have implications
for CVD.
Based upon our systematic review, multiple lines of evi-
dence from laboratory experiments and randomized trialsNutrition & Metabolism 2006, 3:2 http://www.nutritionandmetabolism.com/content/3/1/2
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suggest stearic acid may be neutral, while flavonoids are
likely protective against CVD, the latter of which is well
supported by prospective observational studies that sug-
gest flavonoids may lower the risk of CHD mortality.
Though it has been approximated that eating 50 g of dark
chocolate per day may reduce one's risk of CVD by 10.5%
(95% CI: 7.0%–13.5%) [16], such crude estimates were
based on results from studies of short duration, extrapo-
lated to long term CVD outcomes. Therefore, the highest
priority now is to conduct long-term randomized feeding
trials, beyond short term studies of CVD risk factor inter-
mediates, in order to definitively investigate the impact of
chocolate consumption on cardiovascular outcomes.
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